» Articles » PMID: 21510280

Lymphangiogenic and Angiogentic Microvessel Density in Gallbladder Carcinoma

Overview
Specialty Gastroenterology
Date 2011 Apr 23
PMID 21510280
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: Lymphangiogenesis and angiogenesis are essential for cancer metastasis. The aim of this study was to assess lymphatic microvessel density and microvessel density in human gallbladder carcinoma tissues, detect their correlation with the tumor's clinical pathological properties and evaluate their utilities for resection of gallbladder tumor.

Methodology: Tissue microarray blocks containing primary gallbladder cancer and adjacent normal tissue specimens obtained from 118 patients with gallbladder carcinoma were constructed. Lymphatic microvessel density and microvessel density were quantified using immunohistochemistry. Survival was determined using univariate and multivariate analysis.

Results: Microvessel density correlated with tumor stage and liver metastasis (p < 0.01). Lymphatic microvessel density correlated with tumor stage (p < or = 0.01) and lymph node metastasis (p < or = 0.05).There was a very weak correlation between microvessel density and lymphatic microvesseldensity (p < 0.05, r = 0.282). In univariate and multivariate analysislymphatic microvessel density and microvessel density were independent prognostic factors.

Conclusions: Lymphangiogenesis and angiogenesis played important rolein theprocesses of metastasis of gallbladder carcinoma. Measurements of lymphatic microvessel density and microvessel density can be used to estimate gallbladder cancer metastatic risk and provide some useful information for gallbladder carcinoma surgery.

Citing Articles

Tumor-associated lymphatic vessel density is a postoperative prognostic biomarker of hepatobiliary cancers: a systematic review and meta-analysis.

Li J, Liang Y, Wang Q, Li Y, Chen X, Luo W Front Immunol. 2025; 15():1519999.

PMID: 39840048 PMC: 11747820. DOI: 10.3389/fimmu.2024.1519999.


Gallbladder cancer: current and future treatment options.

Zhou Y, Yuan K, Yang Y, Ji Z, Zhou D, Ouyang J Front Pharmacol. 2023; 14:1183619.

PMID: 37251319 PMC: 10213899. DOI: 10.3389/fphar.2023.1183619.


Targeted Therapies for Perihilar Cholangiocarcinoma.

Gray S, Lamarca A, Edeline J, Klumpen H, Hubner R, McNamara M Cancers (Basel). 2022; 14(7).

PMID: 35406560 PMC: 8997784. DOI: 10.3390/cancers14071789.


Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer.

Wang Y, Chen T, Li K, Mu W, Liu Z, Shi A Front Oncol. 2021; 11:777617.

PMID: 34778094 PMC: 8581488. DOI: 10.3389/fonc.2021.777617.


Overview of current targeted therapy in gallbladder cancer.

Song X, Hu Y, Li Y, Shao R, Liu F, Liu Y Signal Transduct Target Ther. 2020; 5(1):230.

PMID: 33028805 PMC: 7542154. DOI: 10.1038/s41392-020-00324-2.